Efficacy of thalidomide-or lenalidomide-based therapy in proliferative multiple myeloma

Leukemia

Volumn 25, Issue 7, 2011, Pages 1195-1197

  Kapoor, P ^a   Kumar, S ^a   Mandrekar, S J ^a   Laumann, K M ^a   Dispenzieri, A ^a   Lacy, M Q ^a   Dingli, D ^a   Gertz, M A ^a   Kyle, R A ^a   Greipp, P R ^a   Rajkumar, S V ^a   Witzig, T E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MITOTIC INDEX; MULTIPLE MYELOMA; PLASMA CELLS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 79960226207     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.54     Document Type: Article

References (8)

1. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-3387. (Pubitemid 23172924)
2. Boccadoro M, Marmont F, Tribalto M, Fossati G, Redoglia V, Battaglio S et al. Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. J Clin Oncol 1989; 7: 119-125. (Pubitemid 19089090)
3. San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, Ortega F et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448-455.
4. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999; 113: 73-77. (Pubitemid 29354098)
5. Garcia-Sanz R, Gonzalez-Fraile MI, Mateo G, Hernandez JM, Lopez-Berges MC, de las Heras N et al. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer 2004; 112: 884-889. (Pubitemid 39435276)
6. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82: 1179-1184. (Pubitemid 47502875)
7. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323. (Pubitemid 35266292)
8. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009; 114: 518-521.